Related Experiment Videos
Down-regulation of SKP2 induces apoptosis in lung-cancer cells
Sana Yokoi1, Kohichiroh Yasui, Toshihiko Iizasa
1Department of Molecular Cytogenetics, Medical Research Institute, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo 113-8510, Japan.
Abstract:
S-Phase kinase associated protein 2 (SKP2), an F-box protein constituting the substrate-recognition subunit of the SCF(SKP2) ubiquitin ligase complex, targets cell-cycle regulators, such as the cyclin-dependent kinase inhibitor p27(KIP1), for ubiquitin-mediated degradation. Our earlier studies indicated frequent amplification and over-expression of the SKP2 gene in primary small-cell lung cancers (SCLCs) and cell lines derived from this type of tumor, and showed that down-regulation of SKP2 expression by means of an antisense oligonucleotide inhibited the growth of SCLC cells in culture (Yokoi et al., Am J Pathol, 161, 207-216, 2002). The antisense effect was confirmed in two cell lines of non-small cell lung cancer (NSCLC) that also exhibited over-expression of the gene. In the work reported here, we examined the mechanism(s) responsible for antisense-mediated growth inhibition of SCLC- and NSCLC-derived cultures. SKP2-antisense treatment not only suppressed DNA synthesis, as determined by [(3)H]thymidine incorporation, but also induced spontaneous apoptosis characterized by an increase in the sub-G1 population, fragmentation of nuclei, and activation of caspase-3. Our results suggest that since down-regulation of SKP2 appears to induce apoptosis in lung-cancer cells directly, targeting this molecule could represent a promising new therapeutic approach for this type of cancer, and possibly other tumors that over-express SKP2.
Insights
Targeting S-Phase kinase associated protein 2 (SKP2) by down-regulating its expression inhibits lung cancer cell growth. This approach induces apoptosis, suggesting SKP2 as a potential therapeutic target for lung cancer.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- S-Phase kinase associated protein 2 (SKP2) is an F-box protein crucial for the SCF(SKP2) ubiquitin ligase complex.
- SKP2 targets cell-cycle regulators like p27(KIP1) for degradation.
- SKP2 gene amplification and overexpression are frequent in small-cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).
Purpose of the Study:
- To investigate the mechanisms underlying antisense-mediated growth inhibition of SCLC and NSCLC cells.
- To evaluate the therapeutic potential of targeting SKP2 in lung cancer.
Main Methods:
- Utilized antisense oligonucleotides to down-regulate SKP2 expression in SCLC and NSCLC cell lines.
- Assessed DNA synthesis via [3H]thymidine incorporation.
- Analyzed apoptosis induction through sub-G1 population, nuclear fragmentation, and caspase-3 activation.
Main Results:
- SKP2-antisense treatment suppressed DNA synthesis in lung cancer cells.
- This treatment induced spontaneous apoptosis, evidenced by increased sub-G1 population and nuclear fragmentation.
- Caspase-3 activation was observed, confirming the induction of apoptosis.
Conclusions:
- Down-regulation of SKP2 directly induces apoptosis in lung cancer cells.
- Targeting SKP2 represents a promising therapeutic strategy for lung cancer.
- This approach may also be effective for other tumors overexpressing SKP2.
Related Concept Videos
The Intrinsic Apoptotic Pathway
The Extrinsic Apoptotic Pathway
Abnormal Proliferation
Apoptosis
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
Negative Regulator Molecules